Curis, Inc. Investors: Company Investigated by the Portnoy Law Firm

Friday, 18. June 2021 00:42

Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Curis issued a press release on June 11, 2021 announc[ing] updated data from its ongoing Phase 1/2 open-label, single arm, dose escalation and expansion trial of CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) at the European Hematology Association 2021 Virtual Congress (EHA). Specifically, Curis stated that it had concluded 300mg BID is the optimal dose to take into Phase 2 studies after the 500 mg and 400 mg versions of the drug showed dose-limited toxicities.

Curis's stock price fell $4.67 per share, or 36.83%, on this news, to close at $8.01 per share on June 11, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Primary Logo

Related Links: 
Author:
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.